1. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer;Acquaviva;Biochim Biophys Acta,2009
2. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010
3. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers;Katayama;Sci Transl Med,2012
4. Ignatius Ou S-H, Klempner S, Greenbowe J, et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J Thorac Oncol (in press).
5. Two novel ALK mutations mediate acquired resistance to the next-Generation ALK inhibitor alectinib;Katayama;Clin Cancer Res,2014